EUCTR2019-002988-10-DEActive, not recruitingPhase 1
A phase IV, single-blind, randomised, controlled, multi-country study to evaluate the immunogenicity and safety of GSK’s Infanrix hexa (DTPa-HBV-IPV/Hib) versus MCM Vaccine BV’s Vaxelis (DTaP5-HBV-IPV-Hib), when administered intramuscularly according to a 2-, 4- and 12-month schedule in healthy infants and toddlers
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Enrollment
- 500
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •-Subjects' parent(s)/Legally Acceptable Representative(s) (LAR[s]) who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., return for follow-up visits).
- •-Written or witnessed/thumb printed informed consent obtained from the parent(s)/LAR(s) of the subject prior to performing any study specific procedure.
- •-A male or female child between and including 6 and 12 weeks of age (42 to 84 days) at the time of the first vaccination.
- •-Subject born after at least 37 weeks of gestation.
- •-Healthy subjects as established by the investigator based on medical history and the clinical examination before entering into the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 500
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
Exclusion Criteria
- •-Any clinical condition that, in the opinion of the investigator, might pose any risk to the subject due to participation in the study. As with other vaccines, administration of DTPa-HBV-IPV/Hib should be postponed in subjects suffering from acute severe febrile illness. The presence of a minor infection is not a contraindication.
- •-Known history of diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Hib diseases since birth.
- •-History of any reaction or hypersensitivity likely to be caused or exacerbated by any excipient or active component of the vaccine(s).
- •-Any confirmed or suspected immunosuppressive or immunodeficient condition, including malignancies, based on medical history and physical examination (no laboratory testing required).
- •-Family history of congenital or hereditary immunodeficiency.
- •-Major congenital defects, as assessed by the investigator.
- •-Acute or chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined via medical history including physical examination.
- •-Medical history of neurological disorder, including seizures.
- •-Previous vaccination for diphtheria, tetanus, pertussis, HBV, poliomyelitis, Hib diseases and previous vaccination against pneumococcal infection with pneumococcal conjugate vaccine, with the exception of a birth dose of HBV vaccine, which may be given in accordance with local recommendations.
- •-Use of any investigational or nonregistered product (drug, vaccine, or medical device) other than the study vaccine(s) during the period starting 30 days before the first dose of study vaccine(s) (Day -29 to Day 1), or planned use during the study period.
- •-Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose and ending 30 days after the last dose of vaccine(s) with the exception of administration of vaccines given as part of the national immunization schedule and as part of routine vaccination practice, e.g., rotavirus vaccine, that are allowed at any time during the study period. In case emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is organized by public health authorities outside the routine immunization programme, the time period described above can be reduced if necessary for that mass vaccination vaccine, provided this vaccine/product(s) is licensed and used according to its Product Information.
- •-Administration of long-acting immune-modifying drugs in the period starting 30 days before the first dose and at any time during the study period.
- •-Administration of immunoglobulins and/or any blood products or plasma derivatives from birth or planned administration during the study period.
- •-Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first vaccine. For corticosteroids, this will mean prednisone =0.5 mg/kg/day (for paediatric subjects), or equivalent. Inhaled and topical steroids are allowed.
- •-Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a noninvestigational vaccine/product (drug or medical device).
- •-Child in care.
Investigators
Similar Trials
Active, not recruiting
Phase 1
A study to evaluate immunogenicity and safety of GlaxoSmithKline (GSK)'s Infanrix hexa vaccine (DTPa HBV IPV/Hib) versus MCM Vaccine BV's Vaxelis vaccine (DTaP5 HBV IPV Hib) in healthy infants and toddlersEUCTR2019-002988-10-ITGLAXOSMITHKLINE BIOLOGICALS500
Active, not recruiting
Phase 1
Evaluation of the effectiveness of the antibiotic therapy in preventing complications after tooth extraction and evaluation of the effectiveness of the probiotic in preventing antibiotic adverse effectteeth needing extraction due to infectionsMedDRA version: 21.1Level: PTClassification code 10062132Term: Tooth extractionSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 20.0Level: PTClassification code 10044034Term: Tooth disorderSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2016-001916-39-ITAZIENDA OSPEDALIERO-UNIVERSITARIA PISANA150
Not yet recruiting
Phase 4
A clinical study to evaluate the efficacy and safety of Nisha-Amalki capsules in preventing progression to Diabetes in patients with Pre-DiabetesCTRI/2018/08/015503PHARMANZA HERBAL PVT LTD
Not yet recruiting
Phase 4
Immunogenicity and safety of heterologous booster vaccination; with the covid-19 recombinant vaccine (AstraZeneca/Fiocruz), covid-19 mRNA vaccine (Pfizer/Wyeth) or covid-19 recombinant vaccine (Janssen), and homologous with inactivated covid-19 adsorbed vaccine (Sinovac/Butantan)Covid-19D012141RBR-9nn3scwInstituto D'Or de Pesquisa e Ensino
Active, not recruiting
Phase 1
A phase IV, single-blinded, randomized, single centre study to demonstrate the non-inferiority of immunogenicity elicited by GSK Biologicals’ hepatitis B vaccine, Engerix-B in multidose presentation to that elicited by Engerix-B in monodose presentation when administered according to 0, 1, 6 months schedule in healthy adults aged equal to or above 18 years. - HBV-308EUCTR2004-005262-20-BEGlaxoSmithKline Biologicals280